Sabarish Ayyappan1, Basem M William2. 1. Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center (OSUCCC-James), 320 W. 10th Avenue, A352, Columbus, OH, 43210, USA. 2. Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center (OSUCCC-James), 320 W. 10th Avenue, A352, Columbus, OH, 43210, USA. basem.william@osumc.edu.
Abstract
PURPOSE OF REVIEW: The purpose of the study is to summarize the current conundrums in the management of marginal zone lymphomas (MZL). RECENT FINDINGS: In 2017, the US Food and Drug Administration (FDA) approved ibrutinib, a first in class Bruton Tyrosine Kinase inhibitor, for the treatment of relapsed/refractory MZL based on pivotal open-label phase II trial demonstrating an overall response rates of 48%. Clinical trials design utilizing chemotherapy-free regimens for relapsed/refractory disease are gaining popularity. Recent studies have identified multiple genetic biomarkers that helped characterize and prognosticate different subtypes of MZL. MZLs are heterogeneous, mostly indolent, malignancies derived from B lymphocytes. Three disease subtypes are recognized, extranodal, nodal, and splenic. The disease characteristics, clinical picture, and treatment algorithms vary considerably based on subtype and site of involvement. Recent discoveries have enhanced our knowledge of the pathogenesis of MZLs leading to development of more accurate prognostic models as well as novel targeted systemic therapies.
PURPOSE OF REVIEW: The purpose of the study is to summarize the current conundrums in the management of marginal zone lymphomas (MZL). RECENT FINDINGS: In 2017, the US Food and Drug Administration (FDA) approved ibrutinib, a first in class Bruton Tyrosine Kinase inhibitor, for the treatment of relapsed/refractory MZL based on pivotal open-label phase II trial demonstrating an overall response rates of 48%. Clinical trials design utilizing chemotherapy-free regimens for relapsed/refractory disease are gaining popularity. Recent studies have identified multiple genetic biomarkers that helped characterize and prognosticate different subtypes of MZL. MZLs are heterogeneous, mostly indolent, malignancies derived from B lymphocytes. Three disease subtypes are recognized, extranodal, nodal, and splenic. The disease characteristics, clinical picture, and treatment algorithms vary considerably based on subtype and site of involvement. Recent discoveries have enhanced our knowledge of the pathogenesis of MZLs leading to development of more accurate prognostic models as well as novel targeted systemic therapies.
Authors: Shaun Rosebeck; Lisa Madden; Xiaohong Jin; Shufang Gu; Ingrid J Apel; Alex Appert; Rifat A Hamoudi; Heidi Noels; Xavier Sagaert; Peter Van Loo; Mathijs Baens; Ming-Qing Du; Peter C Lucas; Linda M McAllister-Lucas Journal: Science Date: 2011-01-28 Impact factor: 47.728
Authors: F Berger; P Felman; C Thieblemont; T Pradier; L Baseggio; P A Bryon; G Salles; E Callet-Bauchu; B Coiffier Journal: Blood Date: 2000-03-15 Impact factor: 22.113
Authors: A Clipson; M Wang; L de Leval; M Ashton-Key; A Wotherspoon; G Vassiliou; N Bolli; C Grove; S Moody; L Escudero-Ibarz; G Gundem; K Brugger; X Xue; E Mi; A Bench; M Scott; H Liu; G Follows; E F Robles; J A Martinez-Climent; D Oscier; A J Watkins; M-Q Du Journal: Leukemia Date: 2014-11-27 Impact factor: 11.528
Authors: Jennifer R Brown; Jonathan W Friedberg; Yang Feng; Sarah Scofield; Kimberly Phillips; Paola Dal Cin; Robin Joyce; Ronald W Takvorian; David C Fisher; Richard I Fisher; Jane Liesveld; Diana Marquis; Donna Neuberg; Arnold S Freedman Journal: Br J Haematol Date: 2009-03-30 Impact factor: 6.998
Authors: C Kalpadakis; G A Pangalis; M N Dimopoulou; T P Vassilakopoulos; M-C Kyrtsonis; P Korkolopoulou; F N Kontopidou; M P Siakantaris; E M Dimitriadou; S I Kokoris; P Tsaftaridis; E Plata; M K Angelopoulou Journal: Hematol Oncol Date: 2007-09 Impact factor: 5.271
Authors: Ian W Flinn; Richard van der Jagt; Brad S Kahl; Peter Wood; Tim E Hawkins; David Macdonald; Mark Hertzberg; Yiu-Lam Kwan; David Simpson; Michael Craig; Kathryn Kolibaba; Samar Issa; Regina Clementi; Doreen M Hallman; Mihaela Munteanu; Ling Chen; John M Burke Journal: Blood Date: 2014-03-03 Impact factor: 22.113
Authors: Jacob E Robinson; Timothy C Greiner; Alyssa C Bouska; Javeed Iqbal; Christine E Cutucache Journal: Front Oncol Date: 2020-05-08 Impact factor: 6.244
Authors: Lisa Dreessen; Nicolas Maréchal; Michel Verheyden; Ann De Becker; Kristin Jochmans; Tim Vanderhasselt; Bert Bravenboer; Ingo Beyer Journal: BMC Geriatr Date: 2020-06-17 Impact factor: 3.921
Authors: Melissa Lumish; Lorenzo Falchi; Brandon S Imber; Michael Scordo; Gottfried von Keudell; Erel Joffe Journal: J Hematol Oncol Date: 2021-01-06 Impact factor: 17.388